HomeCompareSPFR vs JNJ

SPFR vs JNJ: Dividend Comparison 2026

SPFR yields 23.70% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPFR wins by $71.3K in total portfolio value
10 years
SPFR
SPFR
● Live price
23.70%
Share price
$8.44
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$91.4K
Annual income
$9,823.08
Full SPFR calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — SPFR vs JNJ

📍 SPFR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPFRJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPFR + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPFR pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPFR
Annual income on $10K today (after 15% tax)
$2,014.22/yr
After 10yr DRIP, annual income (after tax)
$8,349.62/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, SPFR beats the other by $7,646.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPFR + JNJ for your $10,000?

SPFR: 50%JNJ: 50%
100% JNJ50/50100% SPFR
Portfolio after 10yr
$55.7K
Annual income
$5,325.43/yr
Blended yield
9.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SPFR
No analyst data
Altman Z
-6.3
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPFR buys
0
JNJ buys
0
No recent congressional trades found for SPFR or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPFRJNJ
Forward yield23.70%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$91.4K$20.0K
Annual income after 10y$9,823.08$827.78
Total dividends collected$56.4K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPFR vs JNJ ($10,000, DRIP)

YearSPFR PortfolioSPFR Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$13,070$2,369.67$10,676$355.77+$2.4KSPFR
2$16,879$2,894.47$11,407$389.39+$5.5KSPFR
3$21,554$3,493.55$12,198$426.53+$9.4KSPFR
4$27,232$4,169.33$13,056$467.62+$14.2KSPFR
5$34,062$4,923.06$13,987$513.12+$20.1KSPFR
6$42,201$5,754.83$14,998$563.56+$27.2KSPFR
7$51,818$6,663.53$16,098$619.52+$35.7KSPFR
8$63,092$7,646.87$17,295$681.69+$45.8KSPFR
9$76,210$8,701.50$18,599$750.82+$57.6KSPFR
10$91,368$9,823.08$20,022$827.78+$71.3KSPFR

SPFR vs JNJ: Complete Analysis 2026

SPFRStock

Jaws Spitfire Acquisition Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company, formerly known as Spitfire Acquisition Corporation, was incorporated in 2020 and is based in Miami Beach, Florida.

Full SPFR Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this SPFR vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPFR vs SCHDSPFR vs JEPISPFR vs OSPFR vs KOSPFR vs MAINSPFR vs ABBVSPFR vs MRKSPFR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.